Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labor/HHS appropriations

This article was originally published in The Tan Sheet

Executive Summary

Bill providing NIH funding for fiscal 2002 awaits President Bush's signature following rush by Congress to pass measure before year-end recess. House approved conference report Dec. 19 in 393-30 vote; Senate passed bill 90-7 on Dec. 20. Legislation gives NIH total program level budget of $22.89 bil. for FY 2002, marking a $2.79 bil. (or 14%) increase over fiscal 2001...

You may also be interested in...



Labor/HHS appropriations

Conference report urges HHS secretary "to form a coordinating unit to review" White House CAM Commission report and "implement ways to better coordinate the department's many CAM-related activities." Conferees also urge secretary "to work with FDA and ODS to resolve [ephedra] rulemaking expeditiously." Appropriations bill, passed by Congress before the holiday recess, provides $17 mil. to ODS (up 70% from FY 2001), $104.6 mil. to NCCAM (up 17.3%) (1"The Tan Sheet" Dec. 24, 2001, In Brief). Conference report also calls for publication of dietary supplement GMPs within 15 days of bill's enactment; however, FDA withdrew GMPs proposed rule from OMB Dec. 19...

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

Topics

UsernamePublicRestriction

Register

PS093437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel